Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jun 28, 2021 5:35pm
139 Views
Post# 33463655

RE:RE:RE:RE:RE:Where things are at

RE:RE:RE:RE:RE:Where things are at

I am not referring to investors at large...I am referring to some investors with a deep knowledge in oncology whom I presume have been contacted ...I think they know more than anyone here .... I think if they bite that increases the odds of success ....does not guarantee but better odds
I am not making a guess on results .... nobody can

Wino115 wrote: I don't think the odds of success go down because investors aren't bidding up the share price. That implies someone has inside information, which the tight lips of THTX have not budged on before. I'm not sure I agree with your logic there on that one. Science determines the odds.

If you're looking for KOL-type affirmation I would say FDA fast track (after all, they see every drug in development, have expertise, and picked TH1902 to fast track on just pre-clinical data), MD Anderson leading the trial, LSA choosing to work with THTX (we heard LSA has turned some firms down). The other KOLs are all the papers written about sortilin overexpression and the Gothenburg guys getting two VCs to back their early stage approach to use sortilin to fight TNBC in a different way.


 

palinc2000 wrote: I must admit that I will be  surprised  if we dont  soon see a a surge in the stock price .
Indeed Securities rules are quite strict when it comes to disclosing material information and you cannot pick and chose who gets access to such info ,
It was and still is my belief that the webminar was just an excuse for the company to be able to  share info a new group of investors (institutinal or otherwise) familier and having expertise in oncology,,,,,So they went fishing and it appears that they have not yet caught one or more big fish.

I dont think this has anything to do with a credibility issue of the past since Paul does not carry that burden,
It is my  sincere belief that if those new prospective investors feel that there is a sound basis for the science that they will jump in before any efficacy results are released,Of course in MOST if not ALL clinical trials there are risks but the big money is made by those who get in before the good news ,
Waiting for results would be akin to making a wager in horse racing when the winning horse is within a few feet from the Finish line,,,,That would never translate to big winnings,
So how do science experts   OUTSIDE  Thera view the science,,BTW Beliveau in my mind is not a true KOL for this platform ,,,,
To summarize the odds of success in Phase 1 would be greater if experts weighed in by taken a substantial position in the stock,,,,BEFORE  any results .....I am sure that there are ongoing discussions with those investors and their representatives so I am very eager to see if the Company can be convincing enough,,,,It has been one week since the webniar so maybe another couple of weeks to go ,,,,,,IF not it does not mean Phase 1 will not be successful but IMO the odds are against us,


 




<< Previous
Bullboard Posts
Next >>